#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Aicardi-Goutieres syndrome Glioblastoma Central nervous system neoplasm Erythema multiforme C3 glomerulopathy Still's disease Ovarian cancer stage III Germ cell cancer Breast cancer metastatic Myeloproliferative neoplasm Sickle cell disease Oesophageal adenocarcinoma Breast cancer Glomerulonephritis rapidly progressive Post transplant lymphoproliferative disorder More trials…

    Learn about Rare Diseases

    Idiopathic inflammatory myopathy – Trials in Disease Idiopathic pulmonary fibrosis – Treatment Cerebral arteriovenous malformation haemorrhagic – Trials in Disease VEXAS syndrome – Diagnostics Focal segmental glomerulosclerosis – Treatment Combined immunodeficiency – Trials in Disease Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome – Basic Information Mitochondrial myopathy Progressive multifocal leukoencephalopathy – Basic Information Retinoblastoma – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Amlodipine Besilate Astegolimab Famotidine Itepekimab Cat Epithelium Extract Aluminium Hydroxide Emapalumab Belantamab Mafodotin L-Threonine Tetrahydrouridine Quemliclustat Omp12 SGN-ALPV Metamizole Magnesium LUMC-BOB1-B7-TCR.1 Bms-986449-03 Selinexor SRSD107 GSKVX000000044501 Trametinib Dimethyl Sulfoxide More therapies…

    Learn about Your Condition

    Plasma cell leukaemia Endotracheal intubation Strongyloidiasis Primary hyperaldosteronism Porphyria non-acute Diabetic gastroparesis Breast cancer Ectopic pregnancy Agitation postoperative Mitral valve incompetence Elderly Anal fissure Myositis Cardiovascular disorder Hand fracture More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Waldenstrom’s macroglobulinaemia refractory

  • A study to evaluate the effectiveness of epcoritamab in patients with Waldenström’s macroglobulinemia that has returned or has not responded to previous treatments.

    Recruiting

    1 1 1
    Investigated Diseases:
    • Waldenstrom’s macroglobulinaemia recurrent
    • Waldenstrom’s macroglobulinaemia
    • Waldenstrom’s macroglobulinaemia refractory
    Investigated Drugs:
    • Epcoritamab
    Belgium Denmark The Netherlands

  • Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Follicular lymphoma stage II
    • Follicular lymphoma stage III
    • Marginal zone lymphoma refractory
    Investigated Drugs:
    • BGB-16673
    • Mosunetuzumab
    • Glofitamab
    Germany Italy Poland

  • Evaluating Sonrotoclax Alone and Combined with Zanubrutinib for Patients with Previously Untreated or Relapsed/Refractory Waldenström Macroglobulinemia

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Waldenstrom’s macroglobulinaemia
    • Waldenstrom’s macroglobulinaemia refractory
    Investigated Drugs:
    • N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
    • Zanubrutinib
    France Greece Italy Spain

  • Study of Acalabrutinib for Patients with Waldenström Macroglobulinemia

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Acalabrutinib
    France Greece Italy

  • Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Waldenstrom Macroglobulinemia Using a Drug Combination

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Waldenstrom’s macroglobulinaemia
    • Waldenstrom’s macroglobulinaemia refractory
    Investigated Drugs:
    • Anhydrous Cyclophosphamide
    • Betamethasone Sodium Phosphate Ph. Eur
    • Brexucabtagene Autoleucel
    Austria France Germany Italy The Netherlands Spain +1

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!